# Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

> **NCT00107432** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 44 (actual)

## Conditions studied

- Epithelial Mesothelioma
- Recurrent Malignant Mesothelioma
- Sarcomatous Mesothelioma
- Stage IA Malignant Mesothelioma
- Stage IB Malignant Mesothelioma
- Stage II Malignant Mesothelioma
- Stage III Malignant Mesothelioma
- Stage IV Malignant Mesothelioma

## Interventions

- **DRUG:** sorafenib tosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00107432
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107432, "Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00107432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*